STOCK TITAN

[Form 4] Elevance Health, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Mark Kaye, EVP & CFO of Elevance Health, Inc. (ELV), reported a sale of 2,895 shares of common stock on 10/02/2025 at a price of $340.24 per share. The filing states this disposition was a payment of tax liability by withholding stock related to the vesting of previously granted restricted stock. After the transaction, the reporting person beneficially owned 16,082 shares directly. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

Mark Kaye, EVP e CFO di Elevance Health, Inc. (ELV), ha riportato la vendita di 2.895 azioni ordinarie in data 10/02/2025 a un prezzo di 340,24 USD per azione. La dichiarazione indica che questa disposizione era un pagamento dell'obbligo fiscale mediante trattenuta di azioni legate al vesting di azioni ristrette precedentemente concesse. Dopo la transazione, la persona che riferisce l'informazione deteneva beneficiariamente direttamente 16.082 azioni. Il Form 4 è stato firmato da un procuratore-in-fatto il 03/10/2025.

Mark Kaye, EVP y CFO de Elevance Health, Inc. (ELV), informó la venta de 2,895 acciones ordinarias el 02/10/2025 a un precio de 340,24 USD por acción. La presentación indica que esta disposición fue un pago de la obligación tributaria mediante retención de acciones relacionada con el vesting de acciones restringidas previamente concedidas. Después de la transacción, la persona reportante poseía beneficiosamente directamente 16.082 acciones. El Formulario 4 fue firmado por un apoderado el 03/10/2025.

Mark Kaye, Elevance Health, Inc. (ELV)의 EVP 겸 CFO로서 2025년 10월 2일에 주당 $340.24의 가격으로 보통주 2,895주를 매도했다고 보고했습니다. 제출서는 이 처분이 이전에 부여된 제한주식의 가속 vesting과 관련된 주식 withholding에 의한 세금 부담의 지급임을 명시합니다. 거래 후 보고자는 직접 16,082주를 경제적으로 보유하게 되었습니다. Form 4는 2025년 10월 3일에 대리인에 의해 서명되었습니다.

Mark Kaye, vice-président exécutif et directeur financier d'Elevance Health, Inc. (ELV), a signalé la vente de 2 895 actions ordinaires le 02/10/2025 à un prix de 340,24 USD par action. Le dépôt indique que cette disposition correspond à un paiement d'impôt par retenue d'actions lié au vesting des actions restreintes préalablement accordées. Après la transaction, la personne déclarant détenait directement 16 082 actions. Le formulaire 4 a été signé par un mandataire le 03/10/2025.

Mark Kaye, EVP & CFO von Elevance Health, Inc. (ELV), meldete den Verkauf von 2.895 Stammaktien am 02.10.2025 zu einem Preis von 340,24 USD pro Aktie. Das Formular gibt an, dass diese Veräußerung eine Zahlung der Steuerverbindlichkeit durch Aktienmitnahme im Zusammenhang mit dem Vesting von zuvor gewährtem Restricted Stock war. Nach der Transaktion hielt die berichtende Person direkt 16.082 Aktien wirtschaftlich berechtigt. Das Formular 4 wurde von einem Bevollmächtigten am 03.10.2025 unterschrieben.

Mark Kaye، نائب الرئيس التنفيذي ومدير المالية في Elevance Health, Inc. (ELV)، أبلغ عن بيع 2,895 سهماً من الأسهم العادية في 10/02/2025 بسعر 340.24 دولاراً للسهم الواحد. تنص الوثيقة على أن هذا التصرف كان دفعاً للالتزام الضريبي عن طريق حجز الأسهم المرتبط باستحقاق الأسهم المقيدة الممنوحة سابقاً. بعد الصفقة، امتلك الشخص المبلغ عنه مباشرةً 16,082 سهماً. تم توقيع النموذج 4 بواسطة وكيل مفوَّض في 03/10/2025.

Mark Kaye,Elevance Health, Inc.(ELV)的执行副总裁兼首席财务官,报告于2025年10月2日以每股 340.24 美元 的价格出售了 2,895 股普通股。该披露文件称此次处置是与尚未归属的限制性股票 vesting 相关的通过股票代扣来支付税款的行为。交易后,报告人直接受益持有 16,082 股。表格 4 由代理签署,日期为 2025年10月3日

Positive
  • Transaction disclosed promptly on Form 4 with transaction date 10/02/2025
  • Specific reason provided: payment of tax liability by withholding for vested restricted stock
Negative
  • None.

Insights

CFO executed a routine tax-withholding sale of vested restricted stock.

The Form 4 shows a 2,895-share disposition at $340.24 on 10/02/2025 specifically described as withholding to pay taxes on vested restricted stock. This is a common, non-discretionary method insiders use to satisfy tax obligations when equity awards vest.

The report also records 16,082 shares still beneficially owned directly, which is the remaining disclosed stake after the withholding event.

Filing appears complete and uses standard Form 4 codes.

The transaction code F and explanation note align with a tax-withholding disposition following vesting. The Form was executed by an attorney-in-fact and includes the required post-transaction beneficial ownership figure, meeting routine Section 16(a) disclosure elements.

Mark Kaye, EVP e CFO di Elevance Health, Inc. (ELV), ha riportato la vendita di 2.895 azioni ordinarie in data 10/02/2025 a un prezzo di 340,24 USD per azione. La dichiarazione indica che questa disposizione era un pagamento dell'obbligo fiscale mediante trattenuta di azioni legate al vesting di azioni ristrette precedentemente concesse. Dopo la transazione, la persona che riferisce l'informazione deteneva beneficiariamente direttamente 16.082 azioni. Il Form 4 è stato firmato da un procuratore-in-fatto il 03/10/2025.

Mark Kaye, EVP y CFO de Elevance Health, Inc. (ELV), informó la venta de 2,895 acciones ordinarias el 02/10/2025 a un precio de 340,24 USD por acción. La presentación indica que esta disposición fue un pago de la obligación tributaria mediante retención de acciones relacionada con el vesting de acciones restringidas previamente concedidas. Después de la transacción, la persona reportante poseía beneficiosamente directamente 16.082 acciones. El Formulario 4 fue firmado por un apoderado el 03/10/2025.

Mark Kaye, Elevance Health, Inc. (ELV)의 EVP 겸 CFO로서 2025년 10월 2일에 주당 $340.24의 가격으로 보통주 2,895주를 매도했다고 보고했습니다. 제출서는 이 처분이 이전에 부여된 제한주식의 가속 vesting과 관련된 주식 withholding에 의한 세금 부담의 지급임을 명시합니다. 거래 후 보고자는 직접 16,082주를 경제적으로 보유하게 되었습니다. Form 4는 2025년 10월 3일에 대리인에 의해 서명되었습니다.

Mark Kaye, vice-président exécutif et directeur financier d'Elevance Health, Inc. (ELV), a signalé la vente de 2 895 actions ordinaires le 02/10/2025 à un prix de 340,24 USD par action. Le dépôt indique que cette disposition correspond à un paiement d'impôt par retenue d'actions lié au vesting des actions restreintes préalablement accordées. Après la transaction, la personne déclarant détenait directement 16 082 actions. Le formulaire 4 a été signé par un mandataire le 03/10/2025.

Mark Kaye, EVP & CFO von Elevance Health, Inc. (ELV), meldete den Verkauf von 2.895 Stammaktien am 02.10.2025 zu einem Preis von 340,24 USD pro Aktie. Das Formular gibt an, dass diese Veräußerung eine Zahlung der Steuerverbindlichkeit durch Aktienmitnahme im Zusammenhang mit dem Vesting von zuvor gewährtem Restricted Stock war. Nach der Transaktion hielt die berichtende Person direkt 16.082 Aktien wirtschaftlich berechtigt. Das Formular 4 wurde von einem Bevollmächtigten am 03.10.2025 unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Kaye Mark

(Last) (First) (Middle)
220 VIRGINIA AVENUE

(Street)
INDIANAPOLIS IN 46204

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Elevance Health, Inc. [ ELV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & CFO
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 F 2,895(1) D $340.24 16,082 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.
Remarks:
/s/ Kathleen S. Kiefer, Attorney in fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Elevance Health CFO Mark Kaye report on Form 4 (ELV)?

The filing reports a sale of 2,895 shares on 10/02/2025 at $340.24 per share to satisfy tax withholding for vested restricted stock.

How many shares does Mark Kaye beneficially own after the transaction?

The Form 4 shows 16,082 shares beneficially owned following the reported transaction.

What was the stated reason for the share disposition on the Form 4?

The filing explicitly states the disposition was a payment of tax liability by withholding stock incident to the vesting of previously granted restricted stock.

What price per share was reported for the transaction?

The reported price was $340.24 per share for the 2,895 shares disposed.

Who signed the Form 4 for the reporting person and when?

The Form 4 was signed by Kathleen S. Kiefer, Attorney in fact on 10/03/2025.
Elevance Health Inc

NYSE:ELV

ELV Rankings

ELV Latest News

ELV Latest SEC Filings

ELV Stock Data

76.61B
224.80M
0.17%
93.25%
1.2%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
INDIANAPOLIS